← Eichor
Condition: Ataxia Telangiectasia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ataxia Telangiectasia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010031
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Beijing Tide Pharmaceutical Co., Ltd · NCT07371663
Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Phase 1/Phase 2 · 1 location(s) · Timothy Yu · NCT07215416
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 79 location(s) · Artios Pharma Ltd · NCT04657068
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/Phase 2 · 23 location(s) · National Cancer Institute (NCI) · NCT05691491
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Phase N/A · 1 location(s) · Hadassah Medical Organization · NCT00874783
The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.